While MUC16 as a standalone biomarker does not significantly impact survival outcomes in NSCLC patients, albeit with a discernible trend, its integration with IL-24 into a biomarker panel reveals a substantial improvement in OS. Here, IL24 is linked to non-small cell lung carcinoma.